New drug study aims to control rare genetic tumor disorder
NCT ID NCT07167329
Summary
This study is testing how well the drug belzutifan works for controlling tumors in people with von Hippel-Lindau (VHL) syndrome, a rare genetic condition that causes tumors in multiple organs. Researchers will follow 100 patients in Brazil to see how effectively the drug shrinks tumors, what side effects occur, and how treatment affects quality of life and healthcare costs. The study will also track blood-related side effects and whether supplemental treatments help manage them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA/PARAGANGLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AC Camargo Cancer Center
RECRUITINGSão Paulo, São Paulo, 01509900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.